MAPT and Alzheimer disease: RO7105705, a pan-tau antibody targeted at N-terminus of all six isoforms of human tau, is now in Phase I trial which evaluates once weekly 8400 mg doses of the antibody in healthy controls and AD patients (NCT02820896; AAIC 2017 Conference News).